Supporting Early Phase Oncology Research With The Right Data Management System

By Rod McGlashing, Data Science Subject Matter Expert

The impending surge in global spending on cancer medications, projected to reach $375 billion by 2027, is set against a backdrop of a 22% forecasted increase in oncology trial initiations from 2018 to 2022. As the industry gears up for this growth, there's a strong emphasis on the imperative need for robust data management solutions. These solutions are essential for navigating the complexities of oncology trials and meeting stringent regulatory demands for faster trials and precise dosing.

Within this context, initiatives by the FDA to expedite cancer research and improve patient outcomes take center stage. Moreover, the critical role of adopting appropriate technology for efficient and secure data collection in early-phase oncology trials is underscored. This includes leveraging electronic Clinical Outcome Assessments (eCOA) and electronic Patient-Reported Outcomes (ePRO) to enhance participant and regulatory compliance while also reducing operational costs and streamlining reimbursement processes.

Additionally, the article sheds light on the significance of Randomization & Trial Supply Management (RTSM) in ensuring timely and accurate delivery of Investigational Products. It calls for Clinical Data Management Systems (CDMS) or Electronic Data Capture (EDC) platforms capable of seamless integration with various solutions.

Looking toward the future, the article highlights the modest approval rate of Phase I oncology drugs and predicts that an evolving understanding of cancer biology will significantly influence forthcoming clinical trials. Consequently, companies are urged to devise a data capture strategy rooted in appropriate technology to effectively adapt to these changes.

Explore this topic further by reading the full article and downloading the CDMS/EDC Buyers Guide, which will enable readers to secure the right system tailored for the evolving landscape of early-phase oncology research.